Amicus falls after suspending AT2220 trial

Amicus (NASDAQ:FOLD) lost $1.45 (15%) to $8.06 on Friday after the company suspended enrollment in a Phase II trial of AT2220 to treat Pompe's disease following two serious adverse events and FDA placed the trial on clinical hold. Amicus said the trial had enrolled only two patients, who had self-described increased muscle weakness at the starting dose of 2.5 g/day. The company said it was a much higher dose than administered in Phase I testing. Amicus plans to evaluate the data and work with FDA to amend the protocol and restart the trial. The open-label, international trial was evaluating the safety of different dosing regimens of oral AT2220 in 18 patients for 12 weeks. ...